Terns to Present at the Cowen 41st Annual Health Care Conference
24 February 2021 - 8:35AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced that
management will be presenting at the Cowen 41st Annual Health
Care Conference on Thursday, March 4 at 9:50 a.m. ET.
A live audio webcast of the presentation will be
available here and on Terns’ website at
http://ir.ternspharma.com/. A replay of the webcast will be
archived on Terns’ website for 30 days following the
presentation.
Terns will also participate in a NASH panel at the conference on
Tuesday, March 2 from 12:50-1:50 p.m. ET.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
programs are based on clinically validated and complementary
mechanisms of action to address the multiple hepatic disease
processes of NASH in order to drive meaningful clinical benefits
for patients. For more information, please visit
www.ternspharma.com.
US Media Contact:Investor Relations
Contact:Mark Vignola investors@ternspharma.com
Media Contact: Cory
Trombleemedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2024 to May 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2023 to May 2024